Long-Term Follow-Up Study of Clinical Study Subjects Treated with An Autologous T Cell Product Expressing An Antibody-Coupled T-Cell Receptor (ACTR)

Conditions

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

What is the purpose of this trial?

Subjects treated with an ACTR product may participate in this long-term follow-up study after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use, named patient Investigational New Drug application, expanded access program, or equivalent setting. No investigational product or treatment will be administered in this study. These subjects will be followed for safety monitoring on a schedule of decreasing frequency through 15 years post-ACTR treatment, in accordance with US FDA Regulatory guidance pertaining to long-term safety follow-up for study subjects receiving recombinant DNA-containing investigational products.

  • Trial with
    Unum Therapeutics
  • Start Date
    03/23/2019
  • End Date
    11/30/2035
Trial Image

For more information about this study, contact:

Laura Leary

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

  • Last Updated
    08/20/2019
  • Study HIC
    #2000024211